Form 4: Tectonic Therapeutic COO Reports Acquisition and Conversion of Stock and Options Following Merger

Christian Cortis, Chief Operating Officer of Tectonic Therapeutic, reports the acquisition and conversion of common stock and stock options following the merger with AVROBIO, Inc.

Summary

• On June 20, 2024, Christian Cortis, the Chief Operating Officer of Tectonic Therapeutic, Inc., reported changes in beneficial ownership of securities following the merger between Tectonic and AVROBIO, Inc.
• As a result of the merger, Cortis received 126,368 shares of Tectonic Therapeutic common stock in exchange for 236,458 shares of Tectonic common stock.
• Additionally, outstanding options to purchase shares of Tectonic common stock were assumed by the Issuer and converted into options to purchase the Issuer's common stock.
• Cortis acquired options to purchase 56,061 shares at an exercise price of $2.38 and 18,704 shares at an exercise price of $5.38.
• The options vest over time, subject to Cortis's continued service to the Issuer.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The filing reflects a standard corporate action (merger) and the executive's continued involvement with the company is incentivized through stock options. There are no explicit negative indicators.

Positives

• The merger provides Cortis with a significant stake in the combined company through stock and options.
• The vesting schedules for the options incentivize continued service to the Issuer.

Risks

• The value of the stock and options is subject to market fluctuations and the performance of Tectonic Therapeutic, Inc.
• The vesting of the options is contingent upon Cortis's continued employment with the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options.

Industry Context

This Form 4 filing reflects the standard reporting requirements for corporate insiders following a significant corporate event such as a merger. It provides transparency into the ownership changes and potential future equity holdings of key executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, aligning with SEC regulations.
• The vesting schedules and exercise prices of the stock options are typical components of executive compensation packages in the biotechnology industry, similar to those offered by companies like Amgen, Regeneron, and Biogen.

Stakeholder Impact

• Shareholders are impacted by the merger and the resulting changes in the company's stock structure.
• Employees, including Christian Cortis, are impacted by the vesting schedules of the stock options, which incentivize continued service.

Key Dates